Preview

Rheumatology Science and Practice

Advanced search

CLINICAL SIGNIFICANCE OF CALPROTECTIN IN RHEUMATIC DISEASES

https://doi.org/10.14412/1995-4484-2018-494-499

Abstract

Calprotectin (CP) belongs to the S100 leukocyte protein family, consists of two calcium-binding protein molecules, S100A8 and S100A9 (MRP8/14, calgranulin A/B). MRP8/14 is the main intracellular protein of neutrophil granulocytes and monocytes, which exerts a proinflammatory effect on phagocytes, endothelial cells in vitro and favors the development of the inflammatory process in vivo; it is an important mediator of many regulatory functions, such as chemotaxis; activation of neutrophil degranulation and phagocytosis; inhibition of immunoglobulin synthesis, cell proliferation and differentiation. CP is currently considered as a potential acute-phase marker in many inflammatory and autoimmune diseases. In rheumatoid arthritis (RA), CP maintains chronic inflammation, by activating the endothelium and increasing the migration of neutrophils into the inflamed synovial fluid. A number of studies have demonstrated the role of CP in monitoring RA activity, detecting subclinical inflammation, and predicting disease exacerbations. CP is of great importance in monitoring the efficiency of RA therapy with disease-modifying antirheumatic drugs and biological agents. The value of CP in spondyloarthritis (SpA) is ambiguous: on the one hand, this marker is highly expressed in the synovial tissue of patients with SpA and correlates with the level of acute-phase reactants; on the other hand, its correlation with disease activity indices is very contradictory and requires further clarification. By and large, CP is a promising laboratory marker of great clinical significance.

About the Author

A. S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology, Moscow
Russian Federation


References

1. Ometto F, Friso L, Astorri D, et al. Calprotectin in rheumatic diseases. Exper Biol Med. 2017;242:859-73. doi: 10.1177/1535370216681551

2. Chen YS, Yan W, Geczy CL, et al. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther. 2009;11:R39. doi: 10.1186/ar2645

3. Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med. 2010;16:713-7. doi: 10.1038/nm.2150

4. Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol. 1998;160:1427-35.

5. Uchida T, Fukawa A, Uchida M, et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res. 2002;1:495-9. doi: 10.1021/pr025531w

6. Van Lent PL, Grevers L, Blom AB, et al. Myeloid-related proteins S100A8/S100A9 regulate joint inflammation and cartilage destruction during antigen-induced arthritis. Ann Rheum Dis. 2008;67:1750-8. doi: 10.1136/ard.2007.077800

7. Viemann D, Strey A, Janning A, et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 2005;105:2955-62.

8. doi: 10.1182/blood-2004-07-2520

9. Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood. 2004;104:4260-8. doi: 10.1182/blood-2004-02-0446

10. Averill MM, Barnhart S, Becker L, et al. S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and den-dritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation. 2011;123:1216-26. doi: 10.1161/CIR-CULATIONAHA.110.985523

11. Chih-Ru L, Tong-You WW, Hsien-Yu T, et al. Glycosylation-dependent interaction between CD69 and S100A8/S100A9 complex is required for regulatory T-cell differentiation. FASEB J. 2015;29:5006-17. doi: 10.1096/fj.15-273987

12. Kopec-Medrek M, Widuchowska M, Kucharz E. Calprotectin in rheumatic diseases: a review. Reumatologia. 2016;54:6. doi: 10.5114/reum.2016.64907

13. Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155(1):49-55. doi: 10.1016/j.ahj.2007.08.018

14. Peng WH, Jian WX, Li HL, et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2011 May 18;10:41. doi: 10.1186/1475-2840-10-41

15. Garcia-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis. Mol Diagn Ther. 2013;17:49-56.

16. doi: 10.1007/s40291-013-0016-9

17. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA. 2010;303:1266-73. doi: 10.1001/jama.2010.375

18. Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2012;71:974-80.

19. doi: 10.1136/annrheumdis-2011-200598

20. Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2011;70:2075-81. doi: 10.1136/ard.2011.152496

21. Jonsson MK, Hammer HB, Nordal HH, et al. Calprotectin levels correlate with inflammation in early rheumatoid arthritis before disease-modifying antirheumatic drug treatment and after 12 months of treatment [abstract]. Arthritis Rheum. 2016;68 Suppl 10. https://acrabstracts.org/abstract/calprotectin-levels-correlate-with-inflammation-in-early-rheumatoid-arthritis-before-disease-modifying-antirheumatic-drug-treatment-and-after-12-months-of-treatment/. Accessed July 17, 2018.

22. Jonsson MK, Sundlisaeter NP, Nordal HH, et al. Calprotectin as a marker of inflmmation in patients with early rheumatoid arthritis. Ann Rheum Dis. 2017;76:2031-7. doi:10.1136/annrheumdis-2017-211695

23. Soliman A, Elnadya B, Shakerc R, Mansour A. Potential role of calprotectin as a monitoring biomarker for clinical and sonographic activity and treatment outcome in recent-onset rheumatoid arthritis. Egypt Rheumatol Rehabil. 2016;43(3). doi: 10.4103/1110-161X.189824

24. Inciarte-Mundo J, Victoria Hernandez M, Ruiz-Esquide V, et al. Serum calprotectin versus acute-phase reactants in the discrimination of inflammatory disease activity in rheumatoid arthritis patients receiving tumor necrosis factor inhibitors. Arthritis Care Res. 2016;68:899-906. doi: 10.1002/acr.22795

25. Inciarte-Mundo J, Ruiz-Esquide V, Hernandez MV, et al. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology. 2015;54:2239-43. doi: 10.1093/rheumatology/kev251

26. Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66:1093-7. doi: 10.1136/ard.2006.064741

27. Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:499-505. doi: 10.1136/annrheumdis-2013-203923

28. Nair SC, Welsing PMJ, Choi IYK, et al. A personalized approach to biological therapy using prediction of clinical response based on MRP8/14 serum complex levels in rheumatoid arthritis patients. PLoS ONE. 2016;11(3): e0152362. doi: 10.1371/journal.pone.0152362

29. Choi IY, Gerlag DM, Holzinger D, et al. From synovial tissue to peripheral blood: Myeloid related protein 8/14 is a sensitive bio-marker for effective treatment in early drug development in patients with rheumatoid arthritis. PLoS ONE. 2014;9(8):e106253. doi: 10.1371/journal.pone.0106253

30. Tweehuysen L, den Broeder N, Joosten LAB, et al. No added predictive value of serum calprotectin for treatment response to adalimumab or etanercept in RA patients [abstract]. Arthritis Rheum. 2017;69 Suppl 10. https://acrabstracts.org/abstract/no-added-predictive-value-of-serum-calprotectin-for-treatment-response-to-adalimumab-or-etanercept-in-ra-patients/. Accessed July 17, 2018.

31. Pchelintseva AO, Zhornyak AP, Ionichenok NG, et al. Changes in calprotectin level, its relationship to the clinical and laboratory parameters of disease activity and significance for predicting the therapeutic response in rheumatoid arthritis patients treated with etanercept. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;53(4):379-84 (In Russ.)]. doi: 10.14412/1995-4484-2015-379-384

32. Moncrieffe H, Ursu S, Holzinger D, et al. A subgroup of juvenile idiopathic arthritis patients who respond well to methotrexate are identified by the serum biomarker MRP8/14 protein. Rheumatology (Oxford). 2013;52:1467-76. doi: 10.1093/rheumatology/ket152

33. Smith S, Plant D, Eyre S, et al. The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. Rheumatology. 2017;56:1019-24. doi: 10.1093/rheumatology/kew387

34. Obry A, Lequerre T, Hardouin J, et al. Identification of S100A9 as Biomarker of Responsiveness to the Methotrexate/Etanercept Combination in Rheumatoid Arthritis Using a Proteomic Approach. PLoS ONE. 2014;9(12):e115800. doi: 10.1371/journal.pone.0115800

35. Inciarte-Mundo J, Ramirez J, Hernandez MV, et al. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Res Ther. 2016;18:160. doi: 10.1186/s13075-016-1032-z

36. Guo Q, Zha X, Li C, et al. Serum calprotectin - a promising diagnostic marker for adult-onset Still's disease. Clin Rheumatol. 2016;35:73-9. doi: 10.1007/s10067-015-3108-6

37. Kruithof E, De Rycke L, Vandooren B, et al. Identification of syn-ovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 2006;54:1795-804. doi: 10.1002/art.21914

38. De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNF treatment of infiltrating versus resident tissue macrophage subsets in auto-immune arthritis. J Pathol. 2005;206:17-27. doi: 10.1002/path.1758

39. Oktayoglu P, Bozkurt M, Mete N, et al. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with anky-losing spondylitis and its association with disease activity and quality of life. J Invest Med. 2014;62:880-4. doi: 10.1097/JIM.0000000000000095

40. Turina MC, Yeremenko N, Paramarta JE, et al. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis. Arthritis Res Ther. 2014;16:413. doi: 10.1186/s13075-014-0413-4

41. Duran A, Kobak S, Sen N, et al. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci. 2015;16:71-4.

42. Klingberg E, Carlsten H, Hilme E, et al. Calprotectin in ankylosing spondylitis – frequently elevated in faeces, but normal in serum. Scand J Gastroenterol. 2012;47:435-44.

43. doi: 10.3109/00365521.2011.648953

44. Cypers H, Varkas G, Beeckman S, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75:1357-62. doi: 10.1136/annrheumdis-2015-208025

45. Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014;73:1746-8. doi: 10.1136/annrheumdis-2014-205506

46. Huang J, Yin Z, Song G, et al. Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis. Dis Markers. 2017;2017:Article ID 7574147. 5 p. doi: 10.1155/2017/7574147

47. Van Praet L, Jacques P, van den Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol. 2012 Apr 17;8(5):288-95. doi: 10.1038/nrrheum.2012.42


Review

For citations:


Avdeeva A.S. CLINICAL SIGNIFICANCE OF CALPROTECTIN IN RHEUMATIC DISEASES. Rheumatology Science and Practice. 2018;56(4):494-499. (In Russ.) https://doi.org/10.14412/1995-4484-2018-494-499

Views: 1474


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)